Bio-Techne To Present At The Jefferies 2018 Healthcare Conference

MINNEAPOLIS, May 24, 2018 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, will present at the Jefferies 2018 Healthcare Conference on Tuesday, June 5, 2018, at 2:00 p.m. EDT. The conference will be held at the Grand Hyatt New York in New York City.

A live webcast of the presentation can be accessed via Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ or through the following link http://wsw.com/webcast/jeff113/tech/.

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins––notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD's in-situ hybridization detection products --- which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotech Division, headquartered in Minneapolis, Minnesota.  The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $563 million in net sales in fiscal 2017 and has approximately 1,800 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

View original content with multimedia:http://www.prnewswire.com/news-releases/bio-techne-to-present-at-the-jefferies-2018-healthcare-conference-300654129.html

SOURCE Bio-Techne Corporation